comparemela.com

Latest Breaking News On - Greg zante - Page 4 : comparemela.com

HC Wainwright Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $90.00 target price on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 6.26% from the stock’s previous close. […]

Viking Therapeutics (NASDAQ:VKTX) Earns Buy Rating from HC Wainwright

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 6.26% from the stock’s previous close. […]

Viking Therapeutics (NASDAQ:VKTX) PT Raised to $138 00

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) had its target price raised by equities research analysts at Oppenheimer from $116.00 to $138.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would indicate a potential upside of 65.27% from the stock’s […]

Viking Therapeutics (NASDAQ:VKTX) PT Raised to $138 00

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) had its price objective raised by research analysts at Oppenheimer from $116.00 to $138.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 65.27% from the company’s previous […]

Viking Therapeutics (NASDAQ:VKTX) PT Raised to $138 00

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) had its target price raised by equities research analysts at Oppenheimer from $116.00 to $138.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would indicate a potential upside of 65.27% from the stock’s […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.